- Home
- CCEL vs FGEN Comparison
CCEL vs FGEN Comparison
Compare CCEL & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- FGEN
- Stock Information
- Founded
- CCEL 1989
- FGEN 1993
- Country
- CCEL United States
- FGEN United States
- Employees
- CCEL N/A
- FGEN N/A
- Industry
- CCEL Managed Health Care
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- FGEN Health Care
- Exchange
- CCEL Nasdaq
- FGEN Nasdaq
- Market Cap
- CCEL 39.9M
- FGEN 33.5M
- IPO Year
- CCEL 1997
- FGEN 2014
- Fundamental
- Price
- CCEL $4.81
- FGEN $7.80
- Analyst Decision
- CCEL Strong Buy
- FGEN Strong Buy
- Analyst Count
- CCEL 1
- FGEN 1
- Target Price
- CCEL $8.50
- FGEN $250.00
- AVG Volume (30 Days)
- CCEL 14.5K
- FGEN 61.0K
- Earning Date
- CCEL 07-15-2025
- FGEN 08-05-2025
- Dividend Yield
- CCEL 12.42%
- FGEN N/A
- EPS Growth
- CCEL N/A
- FGEN N/A
- EPS
- CCEL N/A
- FGEN N/A
- Revenue
- CCEL $31,988,783.00
- FGEN $6,996,000.00
- Revenue This Year
- CCEL $2.49
- FGEN N/A
- Revenue Next Year
- CCEL $0.95
- FGEN N/A
- P/E Ratio
- CCEL N/A
- FGEN N/A
- Revenue Growth
- CCEL 1.10
- FGEN N/A
- 52 Week Low
- CCEL $4.68
- FGEN $4.50
- 52 Week High
- CCEL $9.43
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- CCEL 43.31
- FGEN 67.08
- Support Level
- CCEL $4.75
- FGEN $7.03
- Resistance Level
- CCEL $5.05
- FGEN $5.73
- Average True Range (ATR)
- CCEL 0.19
- FGEN 0.57
- MACD
- CCEL -0.01
- FGEN 0.35
- Stochastic Oscillator
- CCEL 14.71
- FGEN 100.00
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.